RAP2C

Across TCGA pan-cancer cohorts, RAP2C mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RAP2C data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RAP2C mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RAP2C expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where RAP2C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	1.000	0.883	.002	34	view →
PDAC	DFS	Tertile	II,III,IV	0.241	0.588	.004	24	view →
HNSC	DFS	Tertile	All	0.789	0.553	.021	23	view →
CCRCC	OS	Tertile	All	0.732	0.934	.012	11	view →
GBM	DFS	Median	All	0.261	0.478	.013	3	view →
LSCC	DFS	Median	III,IV	1.000	0.867	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RAP2C–LUAD (OS)

Open the LUAD breakdown →